101079-63-4

Basic information

• Product Name: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE
• Synonyms: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE;3,4-Diamino-2,6-dichloropyridine;2,6-Dichloro-3,4-pyridinediamine;6-dichloropyridine-3;6-dichloro-3,4-pyridinediaMine;3,4-PyridinediaMine, 2,6-dichloro-;2,6-DICHLOROPYRIDINE-3,4-DIAM
• CAS NO: 101079-63-4
• Molecular Formula: C5H5Cl2N3
• Molecular Weight: 178.02
• Product Categories: Heterocycle-Pyridine series
• Mol File: 101079-63-4.mol
• Article Data: 20

Chemical Properties

• Melting Point: 181-183℃
• Boiling Point: 424.014 °C at 760 mmHg
• Flash Point: 210.236 °C
• Appearance: /
• Density: 1.602 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.693
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.50±0.50(Predicted)
• CAS DataBase Reference: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(101079-63-4)
• EPA Substance Registry System: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(101079-63-4)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 101079-63-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-DICHLOROPYRIDINE-3,4-DIAMINE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Agricultural Industry:
In the agricultural sector, 2,6-DICHLOROPYRIDINE-3,4-DIAMINE is used as a precursor in the production of agrochemicals. Its reactivity and functional groups make it suitable for the creation of compounds that can be used in pest control and crop protection, enhancing agricultural productivity and crop yields.
Used in Chemical Synthesis:
2,6-DICHLOROPYRIDINE-3,4-DIAMINE is utilized as a building block in the synthesis of a wide range of organic compounds. Its ability to undergo multiple types of reactions makes it a versatile component in the creation of new chemical entities for various applications, including but not limited to materials science, specialty chemicals, and research compounds.

InChI:InChI=1/C5H5Cl2N3/c6-3-1-2(8)4(9)5(7)10-3/h1H,9H2,(H2,8,10)

Upstream product

• 25194-01-8 4-nitro-2,6-dichloro-pyridine 
• 2587-03-3 2,6-dichloro-N-nitro-4-pyridinamine 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 2402-78-0 2,6-dichloropyridine 
• 668268-66-4 3-amino-4-acetamido-2,6-dichloropyridine 
• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 

Downstream Products

• 2589-12-0 4,6-dichloro-1H-imidazo<4,5-c>pyridine 
• 2589-12-0 4,6-dichloro-3H-imidazo[4,5-c]pyridine 
• 579486-60-5 4,6-dichloro-2-methyl-1H-imidazo[4,5-c]pyridine 

Relevant articles and documents

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.

A convenient route for the synthesis of 3-deazaspongosine

The first chemical synthesis of the 3-deazaspongosine nucleoside is described, starting from commercially available 4-amino-2,6-dichloropyridine. The key step is the introduction of required functional groups at the 2 and 6 positions of the 4-amino-3-nitropyridine without any conflict in the synthesis of nucleobase. Regioselective nucleophilic substitution with allyl alkoxide at the 2 position of 4-amino-2,6-dimethoxypyridine, followed by sequential deallylation and chlorination led to the desired 2-chloro derivative. Ring closure of the 3,4-diaminopyridine and stereoselective glycosylation of the imidazo[4,5-c]pyridine with tetraacetate-protected ribofuranose gave only the N9-β-isomer. A final nucleophilic displacement of the 6-chloride by hydrazine followed by reduction with Raney Nickel gave the desired 3-deazaspongosine. The synthesis of 3-deazaspongosine by the stereoselective glycosylation of imidazo[4,5-c]pyridine with tetraacetate-protected ribofuranose is described. The key step is the synthesis of the nucleobase starting from 2,6-dimethoxy-3-nitropyridin-4-amine by introducing the required functional groups at the 2 and 6 positions through the regioselective addition of allyl alcohol. Copyright

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38

The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

CDK INHIBITORS

Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.

AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS

The present invention relates to azabenzimidazole derivatives of Formula (I) (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active 10 ingredient as well as the use of said compounds as a medicament.

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS

A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.